{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 44 of 92', 'CR845-CLIN3103', 'Table 2.', 'Schedule of Events: Double-blind Phase (Continued)', 'Study Procedures', 'Follow-Up', 'Period (for', 'Screening Period', 'patients not', 'participating in', 'Double-blind End', 'Open-label', 'Screening', 'Run-in', 'of Treatmentb/', 'Extension Phase', 'Visit', 'Period', 'Double-blind Treatment Period', 'Early Termination', 'ONLY)', 'Day -28 to', 'Day -7 to', 'First Day of', 'Visit Days', 'Day -7', 'Day 1', 'Week 1', 'Weeks 2 to 12', 'Week 13', 'FU Days 1b -10', 'M/Tu', 'W/Th', 'F/Sa', 'M/Tu', 'W/Th', 'F/Sa', '-28 to -7', '-7 to 1', '1', '3', '5', '8', '10', '12', '85', '85 to 95', '15', '17', '19', '22', '24', '26', '29 k', '31', '33', '36', '38', '40', '43', '45', '47', '50', '52', '54', '57*', '59', '61', '64', '66', '68', '71e', '73', '75', '78', '80', '82', 'Safety and efficacy evaluations', 'Patient training on PRO worksheets', 'Xhi', 'X\u00b9', 'X', 'Worst Itching Intensity NRS (daily)i', 'X', 'Record on an ongoing basis', 'X', 'Skindex-10 Scale, 5-D Itch Scalek', 'Xk', 'Xk', 'Patient Global Impression of Change', 'X', 'Record number of missed dialysis visits and', 'reason(s)', 'Record on an ongoing basis', 'IV administration of study drug', 'Record on an ongoing basis', 'Inflammatory biomarker samples\u00b9', 'X', 'X', 'Adverse event monitoring', 'X', 'X', 'Record on an ongoing basis', 'X', 'X', 'Concomitant medications (including antipruritic', 'Record on an ongoing basis', 'X', 'X', 'medications)', 'Structured Safety Evaluation', 'X', 'X', 'X', 'EoT = End of Treatment; ET = Early Termination; F = Friday; FU = follow-up; IV = intravenous; M = Monday; NRS = numerical rating scale; PRO = patient-reported outcome; Sa = Saturday; Th', '=', 'Thursday; Tu = Tuesday; W = Wednesday', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 45 of 92', 'CR845-CLIN3103', 'a.', \"Each visit during the Double-blind Treatment Period will coincide with the patient's normal dialysis treatments.\", 'b.', 'The End-of-Treatment Visit in the Double-blind Phase will be the first dialysis visit following the last dose of study drug (ie, first dialysis on Week 13 [Day 85]), which also corresponds to Day 1', 'of the Follow-up Period (FU Day 1). Only patients not participating in the Open-label Extension Phase are required to complete the Follow-up', 'Period.', 'c.', 'Medical history will be updated on Day 1 with any changes since the Screening Visit, and inclusion/exclusion criteria will be confirmed prior to randomization. Antipruritic medication will be', 'updated at each dialysis visit during the Run-in Period.', 'd Electrocardiograms must be performed prior to the start of dialysis at Screening, Day 85 (End of Treatment), or at Early Termination visit.', 'e', 'Pre-dialysis vital signs, including body temperature, heart rate, and blood pressure, will be recorded on Days 1, 15, 29, 43, 57, 71 and 85 (End of Treatment), or at Early Termination visit only', 'when the patient is in a sitting or semi-recumbent position. Heart rate will be measured at each dialysis; if heart rate is clinically significant and outside the prespecified visits per the Schedule of', 'Events, the heart rate will be recorded on the relevant CRF page.', 'f', 'Pre-dialysis vital signs, including body temperature, heart rate, and blood pressure, will be recorded at the Follow-up Visit (7-10 days after EoT/ET visit). Heart rate will be measured at each', 'dialysis.', 'g. Blood samples for clinical laboratory evaluation will be taken at Screening, and on Days 1 and 85 (End of Treatment), or at Early Termination visit only.', 'h.', 'Training on Worst Itching Intensity NRS will be conducted prior to the first day of the Run-in Period (Day -7).', 'i.', 'Training on Skindex-10 Scale and 5-D Itch Scale may be performed at any time during Screening prior to randomization on Day 1 of the Double-blind Treatment Period.', 'j.', 'Patients will be requested to complete their Worst Itching Intensity NRS worksheets each day at a similar time (either at home on non-dialysis days around the normal start time of their dialysis or', 'in the dialysis unit). On dialysis days, the worksheets will be completed prior to or during dialysis, but must be completed prior to dosing.', 'k.', '5-D Itch Scale and Skindex-10 Scale completed on Day 1 and the first visit of Weeks 5, 9 and 11 (on Days 29, 57 and 71) and Week 13 (Day 85). The 5-D Itch Scale will preferably be completed', 'first. If the first visit of the week is missed, the patient may complete the worksheets at their next visit for the same week. The worksheets will be completed prior to or during dialysis (preferably', 'within 1 hour of the dialysis), but must be completed prior to dosing.', '1.', 'Biomarker samples must be collected prior to the start of dialysis on Day 1 and Day 85.', 'm.', 'Concomitant medications including antipruritic medication will be updated at each dialysis visit during the Double-blind Treatment Period, and until the end of the Follow-up Period.', 'n.', 'A list of specific signs/symptoms will be verified with the patient by qualified site staff, preferably to be completed on Wednesday/Thursday each week during the Run-in Period, the Double-blind', 'Treatment Period and the Follow-up Period. It is not to be completed on Monday/Tuesday.', 'o.', 'The serum pregnancy test must be performed within 7 days prior to the first study dose.', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}